Table 1.
Potential ALT-targeted drugs.
| Drug Name | Reference | Mechanism of Action | Comments |
|---|---|---|---|
| Anacardic acid | [87] | Inhibits PCAF, a lysine acetyl transferase involved in regulation of APB-related genes | Natural product, not yet entered clinical trials |
| Arsenic Trioxide | [88] | Binds PML protein | Approved for use in the treatment of acute promyelocytic leukemia |
| CX-5461 | [93] | G-quadruplex stabilizer | Currently in clinical trial phase 1 |
| Mirin | [33,82,83] | Inhibits MRN | Small molecule inhibitor, has yet to progress to clinical trial stage |
| PIP-199 | [62] | Inhibitor of the MM2-RMI interaction within FANCM-BTR | Small molecule inhibitor, for research use only. Requires further studies before consideration for clinical trials |
| Quarfloxin | [93] | G-quadruplex stabilizer | Clinical trial terminated in phase 2 |
| Tetra-Pt(bpy) | [94] | Converts telomeric single-stranded DNA to G-quadruplex | Cisplatin derivative, not progressed to clinical trials yet |
| Trabectedin | [90] | Binds minor groove of DNA double helix | ALT positive cells found to be more sensitive than telomerase positive; reason unknown |